Disease relevance of Apicidin A

• Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells [1].
• Apicidin, a novel histone deacetylase inhibitor, has profound anti-growth activity in human endometrial and ovarian cancer cells [2].

High impact information on Apicidin A

• Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase [3].
• Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin [4].
• We previously reported that apicidin, a novel histone deacetylase inhibitor, inhibited the proliferation of tumor cells via induction of p21(WAF1/Cip1) [5].
• Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells [6].
• PURPOSE: Apicidin, a histone deacetylase inhibitor, is a novel cyclic tetrapeptide that exhibits potent antiproliferative activity against various cancer cell lines [6].

Biological context of Apicidin A

• Transcriptional activation of p21(WAF1/CIP1) by apicidin, a novel histone deacetylase inhibitor [7].
• In vitro investigation of the hepatic intrinsic clearance of apicidin, a histone deacetylase inhibitor, in mouse, rat, and human, with correction by nonspecific protein binding [8].

Anatomical context of Apicidin A

• Apicidin, a histone deacetylase inhibitor, induces differentiation of HL-60 cells [9].

Gene context of Apicidin A

• Development of a liquid chromatography/electrospray tandem mass spectrometry assay for the quantification of apicidin, a novel histone deacetylase inhibitor, in rat serum: application to a pharmacokinetic study [10].

References